Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $13.50.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Barclays assumed coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th.

Insider Activity at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This represents a 14.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 231,856 shares of company stock valued at $2,743,724 in the last ninety days. 26.56% of the stock is owned by corporate insiders.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Amneal Pharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock valued at $179,729,000 after acquiring an additional 403,582 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Amneal Pharmaceuticals by 5.3% in the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock valued at $54,361,000 after purchasing an additional 133,764 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after purchasing an additional 558,877 shares during the last quarter. Finally, BlackBarn Capital Partners LP grew its stake in Amneal Pharmaceuticals by 19.6% in the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after purchasing an additional 564,916 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 0.9%

AMRX stock opened at $12.96 on Thursday. The business has a fifty day simple moving average of $11.63 and a 200-day simple moving average of $9.88. The company has a market cap of $4.07 billion, a price-to-earnings ratio of 648.07 and a beta of 1.36. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $12.98.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.